Form 4: Rapport Therapeutics CSO Sells 8,500 Shares
Insider Transaction Disclosure
Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock through a pre-arranged 10b5-1 trading plan.
Summary
- David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), disposed of 8,500 shares of common stock.
- The transactions occurred on September 15, 2025, under a Rule 10b5-1 trading plan adopted on December 12, 2024.
- The first sale involved 5,098 shares at a weighted average price of $23.8841 per share, with prices ranging from $23.42 to $24.41.
- The second sale involved 3,402 shares at a weighted average price of $24.6583 per share, with prices ranging from $24.42 to $24.90.
- Following these transactions, David Bredt beneficially owns 418,142 shares of common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it represents insider selling, the transaction was pre-planned under a Rule 10b5-1 plan, which typically reduces the negative signal often associated with insider dispositions.
Positives
- The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled disposition not based on new, non-public information, which aligns with good corporate governance practices.
Negatives
- Insider selling, even when pre-planned, reduces the direct equity alignment of a key executive with common shareholders.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
Insider transactions, such as those reported in a Form 4, are common occurrences in publicly traded companies. The use of a Rule 10b5-1 trading plan is a standard practice for executives to sell shares in an orderly fashion while mitigating concerns about trading on material non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The reported share sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, demonstrating adherence to established insider trading policies designed to prevent trading on material non-public information. | 09/15/2025 | This practice enhances transparency and reduces potential concerns regarding the timing of insider transactions. |
Stakeholder Impact
- Shareholders may note the reduction in direct equity ownership by a key executive, though the pre-planned nature of the sale mitigates concerns about its implications for the company's immediate prospects.
Key Dates
| Date | Description |
|---|---|
| 12/12/2024 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 09/15/2025 | Date of the reported common stock transactions (sales). |
| 09/17/2025 | Date the Form 4 filing was signed. |
Keywords
Rapport Therapeutics, RAPP, Insider Trading, Form 4, David Bredt, Chief Scientific Officer, Share Sale, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.